Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. Financials
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
Real-time Euronext Paris  -  12:35:01 2023-03-24 pm EDT
0.9190 EUR   +1.10%
03/23Possibility of US Fed's Rate Hike Pause Supports American Depositary Receipts of European Equities
MT
03/23Erytech Pharma S A : ▪Combination with Pherecydes announced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant pathogenic bacteria - Form 6-K
PU
03/22ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 12013965,811,428,5-
Enterprise Value (EV)1 61,112257,411,466,575,1
P/E ratio -1,92x-1,78x-0,93x-0,41x-0,79x-6,13x
Yield ------
Capitalization / Revenue 22,7x37,4x15,7x0,37x0,72x0,61x
EV / Revenue 11,6x32,8x13,7x0,37x1,68x1,60x
EV / EBITDA -1,02x-1,91x-1,12x-0,57x-2,44x11,9x
Enterprise Value (EV) / FCF -0,96x-2,31x-1,01x-2,17x-1,82x-8,73x
FCF Yield -104%-43,3%-99,4%-46,0%-54,9%-11,5%
Price to Book 1,40x4,93x2,20x-0,73x-0,38x-0,34x
Nbr of stocks (in thousands) 17 93819 56231 01631 01631 016-
Reference price (EUR) 6,707,112,120,370,920,92
Announcement Date 03/16/202003/08/202104/27/202203/22/2023--
1 EUR in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 5,283,724,1831,039,746,8
EBITDA1 -59,9-63,8-51,1-52,6-27,26,30
Operating profit (EBIT)1 -64,1-68,8-56,5-2,80-27,26,30
Operating Margin -1 213%-1 851%-1 352%-9,02%-68,5%13,5%
Pre-Tax Profit (EBT) -62,7-73,3-53,8---
Net income1 -62,7-73,3-53,8-0,23-27,4-3,50
Net margin -1 186%-1 971%-1 287%-0,73%-69,0%-7,48%
EPS2 -3,49-3,99-2,27-2,23-1,16-0,15
Free Cash Flow1 -63,4-52,9-57,1-13,8-36,5-8,60
FCF margin -1 201%-1 422%-1 365%-150%-91,9%-18,4%
FCF Conversion 106%82,8%112%26,2%134%-137%
Dividend per Share ------
Announcement Date 03/16/202003/08/202104/27/202203/22/2023--
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 S2 2021 Q1 2021 Q2 2021 S1 2022 Q1 2022 Q3
Net sales1 1,871,440,832,270,540,47
EBITDA -31,0---26,5--
Operating profit (EBIT) -33,5-13,2-15,7-29,0-12,5-
Operating Margin -1 790%-920%-1 894%-1 276%-2 322%-
Pre-Tax Profit (EBT) -38,3-11,9-16,0-28,0-11,9-
Net income1 -38,3-11,9-16,0-28,0-11,9-5,14
Net margin -2 051%-830%-1 929%-1 231%-2 210%-1 093%
EPS -2,04---1,22--
Dividend per Share ------
Announcement Date 03/08/202105/04/202109/20/202109/20/202105/12/202211/21/2022
1 EUR in Million
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ---1,5038,046,6
Net Cash position1 59,117,08,32---
Leverage (Debt / EBITDA) 0,99x0,27x0,16x-0,03x-1,40x7,40x
Free Cash Flow1 -63,4-52,9-57,1-13,8-36,5-8,60
ROE (Net Profit / Equities) -54,2%-131%----
Shareholders' equity1 11656,0----
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share2 4,771,440,96-1,26-2,42-2,69
Cash Flow per Share -2,41-----
Capex 20,11,140,30---
Capex / Sales 381%30,6%7,13%---
Announcement Date 03/16/202003/08/202104/27/2022---
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Key data
Capitalization (EUR) 28 503 752
Capitalization (USD) 30 662 384
Net sales (EUR) 4 180 000
Net sales (USD) 4 496 558
Number of employees 149
Sales / Employee (EUR) 28 054
Sales / Employee (USD) 30 178
Free-Float 98,5%
Free-Float capitalization (EUR) 28 063 895
Free-Float capitalization (USD) 30 189 216
Avg. Exchange 20 sessions (EUR) 234 720
Avg. Exchange 20 sessions (USD) 252 495
Average Daily Capital Traded 0,82%
EPS & Dividend
MarketScreener: Created by Investors for Investors!
100% Free Registration
fermer